Urothelial cancer drugs market seen topping $16 billion by 2030

The urothelial cancer drugs market is projected to grow 19% a year and exceed $16 billion by 2030, driven by higher diagnosis rates, recurring treatment needs and new immunotherapy and targeted therapy launches. Pfizer is expected to lead the market in 2025 with a 28% share, as the top 10 companies control nearly all revenue.

Why it matters: - The urothelial cancer drugs market is moving toward a much larger commercial base, with demand rising alongside an aging population, better diagnostics and more frequent use of advanced cancer therapies. - The market's growth also signals continued investment in immunotherapy, targeted drugs and combination regimens for bladder cancer and related urothelial tumors. - A more concentrated market means big drugmakers and oncology specialists are likely to keep setting the pace on pricing, approvals and treatment standards.

What happened: - The Business Research Company projected that the urothelial cancer drugs market will exceed $16 billion by 2030. - The market is forecast to grow at a 19% compound annual growth rate through 2030. - North America is expected to remain the largest region. - Pfizer is projected to lead the market in 2025 with a 28% share. - The top 10 companies are expected to control about 98% of market revenue in 2025. - The company said the broader Other Oncology Drugs market is expected to reach about $35 billion by 2030, while the wider pharmaceuticals industry is forecast at $2,496 billion. - Urothelial cancer drugs are projected to account for close to 1% of the total pharmaceuticals market value in 2030. - The report included a free sample and full-report access links: Request a free sample and Access the detailed report.

The details: - Urothelial carcinoma is expected to be the largest cancer subtype in the market, representing about 61% of revenue, or roughly $10 billion, by 2030. - Squamous cell carcinoma and adenocarcinoma make up the other major disease segments. - Treatment categories include immunotherapy, chemotherapy and preservation therapy. - Distribution runs through hospital pharmacies, specialty clinics, cancer treatment centers and ambulatory surgical facilities. - North America is projected to reach $5.7 billion by 2030, up from $2.4 billion in 2025, on a 19% CAGR. - The United States is expected to be the largest country market, at about $5.1 billion in 2030 versus $2.2 billion in 2025, growing at 18% annually. - The report attributes growth to aging populations, smoking, occupational exposure and improved diagnostics that expand the patient pool. - Recurrence and the chronic nature of urothelial cancer are expected to add roughly 2.6% annual growth to the market. - Targeted therapies and immunotherapies are expected to contribute about 2.5% annual growth. - Research and development spending is projected to add about 2.4% annual growth. - The report says the market's top growth drivers include PD-1/PD-L1 inhibitors, antibody-drug conjugates, biomarker research and precision medicine. - Pfizer's oncology portfolio includes immunotherapies, targeted therapies, chemotherapy drugs and combination regimens for urothelial carcinoma. - The market's 2025 share breakdown includes Merck & Co. at 26%, Astellas Pharma at 20%, F. Hoffmann-La Roche at 8%, AstraZeneca at 5%, Bristol-Myers Squibb at 4%, Merck KGaA at 3%, ImmunityBio at 2%, UroGen Pharma at 1% and Ferring Pharmaceuticals at 1%. - The source also lists Johnson & Johnson among the market participants. - In July 2026, Pfizer and Astellas received FDA approval for PADCEV plus Keytruda, a platinum-free perioperative regimen for muscle-invasive bladder cancer. - The company said the combination showed better event-free survival, overall survival and complete pathological response than cisplatin-based chemotherapy.

Between the lines: - The market looks set to stay highly consolidated because oncology drug development requires expensive trials, regulatory clearance and proof of safety and efficacy. - The growth story is less about a single breakthrough and more about a stacked set of drivers: more patients, more diagnostic precision and more treatment options. - Pfizer's lead suggests that the biggest near-term wins are likely to come from companies that can pair strong commercial reach with broad oncology pipelines. - The PADCEV-Keytruda approval underscores how perioperative and combination treatments are becoming central to bladder cancer care.

What's next: - Competition is likely to intensify around biomarker-driven therapies, antibody-drug conjugates and immune checkpoint inhibitors. - Pharma and biotech companies are expected to keep expanding clinical trial programs and regulatory submissions for advanced bladder cancer treatments. - The report says strategic partnerships, product innovation and geographic expansion will be key for companies aiming to grow market share.

The bottom line: - The urothelial cancer drugs market is becoming a fast-growing but concentrated oncology segment, with Pfizer and a small group of peers positioned to capture most of the value through 2030.